A randomised placebo controlled trial of VSL#3&#ˣᴬᴱ; probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease

Hepatology

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Lancet.

Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome PN, Sheridan D, Sheikh MY, Trotter J, Knapple W, Lawitz E, Abdelmalek MF, Kowdley KV, Montano-Loza AJ, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud LL, Dufour JF, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal AJ, REGENERATE Study Investigators.

doi: 10.1016/S0140-6736(19)33041-7.

Hepatology

Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial

BMC Gastroenterol.

Saadati S, Sadeghi A, Mansour A, Yari Z, Poustchi H, Hedayati M, Hatami B, Hekmatdoost A

doi: 10.1186/s12876-019-1055-4.

Hepatology

Synbiotic Alters Fecal Microbiomes, but not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Non-alcoholic Fatty Liver Disease

Gastroenterology.

Scorletti E, Afolabi PR, Miles EA, Smith DE, Almehmadi A, Alshathry A, Childs CE, Del Fabbro S, Beavis J, Moyses HE, Clough GF, Sethi JK, Patel J, Wright M, Breen DJ, Peebles C, Darekar A, Aspinall R, Fowell AJ, Dowman JK, Nobili V, Targher G, Delzenne NM, Bindels LB, Calder PC, Byrne CD

doi: 10.1053/j.gastro.2020.01.031.

Hepatology

Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis

Lancet Gastroenterol Hepatol.

Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, Yang H, Liu C, Kam LY, Tan XXE, Chien N, Trinh S, Henry L, Stave CD, Hosaka T, Cheung RC, Nguyen MH

doi: 10.1016/S2468-1253(20)30077-7.

Hepatology

The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease

BMC Gastroenterol.

Trembling PM, Apostolidou S, Gentry-Maharaj A, Parkes J, Ryan A, Tanwar S, Burnell M, Harris S, Menon U, Rosenberg WM

doi: 10.1186/s12876-020-01251-w.

Hepatology

The characteristics and risk factors of hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis

J Gastroenterol Hepatol.

Tobari M, Hashimoto E, Taniai M, Kodama K, Kogiso T, Tokushige K, Yamamoto M, Takayoshi N, Satoshi K, Tatsuo A

doi: 10.1111/jgh.14867.

Hepatology

Patient-reported Outcomes (PROs) in Patients with Non-alcoholic Fatty Liver Disease: A Narrative Review of CLDQ-NAFLD/NASH

J Gastroenterol Hepatol.

Yamamura S, Nakano D, Hashida R, Tsutsumi T, Kawaguchi T, Okada M, Isoda H, Takahashi H, Matsuse H, Eguchi Y, Sumida Y, Nakajima A, Gerber L, Younossi ZM, Torimura T

doi: 10.1111/jgh.15172.

Gastrointestinal CancerHepatology

Risk of Cirrhosis and Hepatocellular Cancer in Patients with Non-Alcoholic Fatty Liver Disease and Normal Liver Enzymes

Hepatology.

Natarajan Y, Kramer JR, Yu X, Li L, Thrift AP, El-Serag HB, Kanwal F

doi: 10.1002/hep.31157.

Hepatitis

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Lancet.

Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, Bansal MB, Baum S, Neuschwander-Tetri BA, Taub R, Moussa SE

doi: 10.1016/S0140-6736(19)32517-6.

Related content

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial

Synbiotic Alters Fecal Microbiomes, but not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Non-alcoholic Fatty Liver Disease

Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis

The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease

The characteristics and risk factors of hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis

Patient-reported Outcomes (PROs) in Patients with Non-alcoholic Fatty Liver Disease: A Narrative Review of CLDQ-NAFLD/NASH

Risk of Cirrhosis and Hepatocellular Cancer in Patients with Non-Alcoholic Fatty Liver Disease and Normal Liver Enzymes

Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial